N+1 Singer restated their corporate rating on shares of Verona Pharma Plc (LON:VRP) in a research report sent to investors on Wednesday.
Shares of Verona Pharma Plc (LON:VRP) opened at 3.19 on Wednesday. Verona Pharma Plc has a 52-week low of GBX 2.58 and a 52-week high of GBX 5.24. The stock’s 50 day moving average price is GBX 3.24 and its 200-day moving average price is GBX 3.32. The company’s market cap is GBX 32.22 million.
About Verona Pharma Plc
Verona Pharma plc is a specialist pharma company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting.